Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MGTX
- Price
- 5.48
- Stock movement up
- +0.28 (5.38%)
- Company name
- MeiraGTx Holdings PLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 428.28M
- Ent value
- 509.16M
- Price/Sales
- 30.75
- Price/Book
- 4.47
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.40%
- 1 year return
- -4.36%
- 3 year return
- -26.05%
- 5 year return
- -16.19%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MGTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 30.75 |
| Price to Book | 4.47 |
| EV to Sales | 36.55 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 78.15M |
| EPS (TTM) | -1.23 |
| FCF per share (TTM) | -1.43 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 13.93M |
| Gross profit (TTM) | -8.46M |
| Operating income (TTM) | -176.48M |
| Net income (TTM) | -88.18M |
| EPS (TTM) | -1.23 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -60.77% |
| Operating margin (TTM) | -1266.97% |
| Profit margin (TTM) | -633.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 122.87M |
| Net receivables | 3.28M |
| Total current assets | 139.05M |
| Goodwill | 0.00 |
| Intangible assets | 951.00K |
| Property, plant and equipment | 149.43M |
| Total assets | 299.49M |
| Accounts payable | 29.50M |
| Short/Current long term debt | 86.73M |
| Total current liabilities | 59.42M |
| Total liabilities | 203.75M |
| Shareholder's equity | 95.74M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -95.77M |
| Capital expenditures (TTM) | 6.77M |
| Free cash flow (TTM) | -102.53M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -92.10% |
| Return on Assets | -29.44% |
| Return on Invested Capital | -49.81% |
| Cash Return on Invested Capital | -57.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.27 |
| Daily high | 5.52 |
| Daily low | 5.18 |
| Daily Volume | 803K |
| All-time high | 30.01 |
| 1y analyst estimate | 23.25 |
| Beta | 1.25 |
| EPS (TTM) | -1.23 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| MGTX | S&P500 | |
| Current price drop from All-time high | -81.74% | -12.04% |
| Highest price drop | -88.00% | -56.47% |
| Date of highest drop | 24 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -56.08% | -11.07% |
| Avg time to new high | 69 days | 12 days |
| Max time to new high | 1451 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
428.28M
Marketcap category
Small-cap
Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Employees
387
Website
Investor relations
-
SEC filings
CEO
Alexandria Forbes
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page